Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Net Income

Net Income at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$92.53M+37.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$185M-22.5%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$166.56M+1.8%
Arrowhead Research logo
Arrowhead ResearchARWR
-$132.73M-136%
ALN
Alnylam PharmaceuticalsALNY
$205.99M+1,229%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$3.64M-80.8%

Segments

By segment

See full
Reportable Segment-$721.81M-2,255,763%

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's net income?
BioCryst Pharmaceuticals (BCRX) reported net income of -$721.81M in Q1 2026.
How has BioCryst Pharmaceuticals's net income changed year-over-year?
BioCryst Pharmaceuticals's net income decreased by 2255762.5% year-over-year, from $32K to -$721.81M.
What is the long-term trend for BioCryst Pharmaceuticals's net income?
Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's net income has grown at a 9.4% compound annual growth rate (CAGR), from -$184.06M to $263.86M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.